

Keywords: reporting guidelines; oncology; EQUATOR Network; research waste

Reporting guidelines for oncology research: helping to maximise the impact of your research

Angela MacCarthy^{*,1}, Shona Kirtley¹, Jennifer A de Beyer¹, Douglas G Altman¹ and Iveta Simera¹

¹UK EQUATOR Centre, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Windmill Road, Headington, Oxford OX3 7LD, UK

Many reports of health research omit important information needed to assess their methodological robustness and clinical relevance. Without clear and complete reporting, it is not possible to identify flaws or biases, reproduce successful interventions, or use the findings in systematic reviews or meta-analyses. The EQUATOR Network (<http://www.equator-network.org/>) promotes responsible reporting and the use of reporting guidelines to improve the accuracy, completeness, and transparency of health research. EQUATOR supports researchers by providing online resources and training. EQUATOR Oncology, a project funded by Cancer Research UK, aims to support cancer researchers reporting their research through the provision of online resources. In this article, our objective is to highlight reporting issues related to oncology research publications and to introduce reporting guidelines that are designed to aid high-quality reporting. We describe generic reporting guidelines for the main study types, and explain how these guidelines should and should not be used. We also describe 37 oncology-specific reporting guidelines, covering different clinical areas (e.g., haematology or urology) and sections of the report (e.g., methods or study characteristics); most of these are little-used. We also provide some background information on EQUATOR Oncology, which focuses on addressing the reporting needs of the oncology research community.

Health research studies must be reported clearly, accurately, and completely if they are to meaningfully enhance medical knowledge and inform clinical practice. Ambiguous, missing, or misleading information obscures how research was carried out and what was found, limiting critical assessment and impeding further use of published findings. It also wastes the financial and human resources invested in the research (Glasziou *et al*, 2014).

Readers cannot judge the robustness of the methodology used or the reliability of the findings if study methods are reported badly. Further, other researchers may be prevented from repeating the study (Goodman *et al*, 2016). Poor reporting of clinical details, inconsistent use of terminology and definitions, insufficient information about interventions, incomplete details of statistical methods, and inconsistent or missing reporting of adverse effects also hamper comparisons of findings across studies, which are necessary to determine the best options for patient care and disease prevention.

Oncology research suffers from the reporting inadequacies that afflict all health research. Table 1 gives some examples of the

consequences of poor reporting in different study types in oncology.

Despite early calls by the World Health Organization (Unknown, 1979) and others (Nahum, 1979; Miller *et al*, 1981) to standardise how the results of cancer treatment studies are reported, many recent studies evaluating the quality of oncology clinical trial reporting have found biased and inconsistent reporting to be very common (Duff *et al*, 2010; Peron *et al*, 2012; Vera-Badillo *et al*, 2016). Basing decisions about patient care on incomplete and misleading research findings may have a profoundly negative impact on patients' health and wellbeing.

These reporting problems are avoidable. In this paper, we introduce reporting guidelines – simple but effective tools supporting complete and transparent reporting – and highlight guidelines that are specifically useful for oncology research. We introduce the EQUATOR (Enhancing the QUALity and Transparency Of health Research) Network programme, its online resources, and a new project, EQUATOR Oncology, which is collating oncology-specific resources.

*Correspondence: A MacCarthy; E-mail: angela.maccarthy@ndorms.ox.ac.uk

Received 16 March 2017; revised 21 September 2017; accepted 22 September 2017; published online 22 February 2018



Table 1. Examples of reporting problems in oncology studies

Reporting issue	Examples of poor reporting	Consequences of poor reporting	Reference
Observational studies			
Prognostic studies not published	Completed prognostic studies of biomarkers not published.	Conclusions drawn from systematic reviews may be inaccurate due to the evidence base not being complete (likely publication bias).	Sekula <i>et al</i> (2016)
Epidemiological studies: incomplete reporting of methodology	Under-reporting of methodological aspects of observational studies including: matching, absolute risks, lack of flow diagram and missing data.	Difficult for readers to assess the validity of the studies.	Papathanasiou and Zintzaras (2010)
Prognostic factor studies: methods poorly reported	Inadequate reporting of aspects of study design and implementation in studies of prognostic markers, including: power calculations, time of enrolment, lists of candidate variables, definition of outcomes and providing the assay reference.	Studies are often too small to detect modest effects, and results from a number of studies may be examined together in systematic reviews or meta-analyses. If methods and findings are not reported in sufficient detail, it is not possible to include studies in such reviews.	Kyzas <i>et al</i> (2007)
Clinical trials: results			
Results not published	Trial findings that have been presented at professional meetings remain unreported or there is a delay in reporting.	Publication bias limits the available evidence base and, if decision to not publish is driven by results, distorts the overall evidence picture (likely publication bias). This can lead to treatments being used based on overoptimistic published results.	Tam <i>et al</i> (2011)
Inconsistencies within publications	Differences between reporting in abstracts and the main body of the text of the published articles: for example, strong support for the experimental arm of the study in the abstract, but not in the main text of the report.	Busy clinicians and policymakers may only read the abstract of the article. Reading only the published abstract may lead to a distorted view of the overall study findings, with implications for physicians when making decisions about clinical care.	Altwaigi <i>et al</i> (2012)
Data published but with deficiencies	Poor reporting of adverse event collection, description of AE characteristics leading to withdrawals, and whether AEs were attributed to trial interventions.	If information about effects of complex, (often combined) therapies are unavailable, could invalidate the decision-making process for clinicians and their patients.	Peron <i>et al</i> (2013)
	Poor reporting of adverse events in surgery, lack of standardised description of adverse events.	Physicians cannot assess the benefits and risks to patients that are likely to be offered surgery.	Meghelli <i>et al</i> (2016)
Poor reporting of trial outcomes	Trial outcomes: Selective trial outcome reporting, such as a discrepancy between the planned and published primary trial endpoints. Lack of reporting of planned non-primary trial endpoints.	Difficult to reproduce studies with poor reporting of outcomes. Overestimation of intervention effect sizes, which has an impact on evidence-based clinical decision making.	Raghav <i>et al</i> (2015)
	Patient-reported outcomes (PROs), quality of life: Poor reporting of methods of PRO collection and analysis, the pre-specified PRO hypothesis, methods for PRO collection and statistical approaches for dealing with missing data.	Patient-reported outcomes are essential in oncology trials. In conjunction with primary outcomes, such as survival, to allow the assessment of benefits and harms associated with the treatment. They are the 'voice' of the patients in the trial and therefore provide a unique perspective on the treatment; they should be addressed in the trial report.	Bylicki <i>et al</i> (2015)
Clinical trials: methods			
	Trial interventions – Chemotherapy: Poor reporting of the relative dose intensity, dose modification, early treatment discontinuation.	Replication and translation into clinical practice is impossible if there is not detailed information on the treatment administered under trial conditions.	Altwaigi <i>et al</i> (2015)

THE EQUATOR NETWORK

The EQUATOR Network was set up in 2006 to support the implementation of reporting guidelines. Along with its database of reporting guidelines, the EQUATOR programme provides resources and toolkits to help researchers write complete and transparent health research papers. Resources are also provided for journal editors and peer reviewers to help ensure that published research is 'fit for purpose', that is, that it provides all of the information needed for its assessment and further use. The Network also organises events and conferences to raise awareness of poor reporting and its consequences, and offers training for researchers and editors to maximise the value of their published research. Ongoing work is expanding the scope of EQUATOR's resources to also cover guidance for research planning. More information about the EQUATOR Network is available on our website (<http://www.equator-network.org/about-us/>).

EQUATOR's scope is primarily studies of humans and pre-clinical animal research. We do not address laboratory research. Related resources for such research tend to target data sharing, such as MIAME for microarray experiments (Brazma *et al*, 2001; <https://fairsharing.org/>).

REPORTING GUIDELINES

Reporting guidelines provide one solution to the widespread problems in research reporting. They are simple, efficient tools, most often in the form of a checklist, that help researchers to prepare manuscripts that contain all of the information required by readers and those that will use the research report.

Table 2 lists the generic guidelines for the main research study types. Most of these guidelines provide a reporting framework for a whole research paper and list the minimum information that authors should include within the paper so that their study can be

Table 2. Generic reporting guidelines available in the EQUATOR Network database of reporting guidelines

Guideline abbreviation	Scope of reporting guideline	Link to further details about the guideline in the EQUATOR Network database
CONSORT	Parallel group randomised trials (extensions address other designs)	Schulz <i>et al</i> , 2010, http://www.equator-network.org/reporting-guidelines/consort/
STROBE	Observational studies in epidemiology: cohort, case-control studies, cross-sectional studies	von Elm <i>et al</i> , 2007, http://www.equator-network.org/reporting-guidelines/strobe/
PRISMA	Systematic reviews and meta-analyses (in particular of randomised trials)	Moher <i>et al</i> , 2009, http://www.equator-network.org/reporting-guidelines/prisma/
CARE	Clinical case reports	Gagnier <i>et al</i> , 2014, http://www.equator-network.org/reporting-guidelines/care/
SRQR	Qualitative research	O'Brien <i>et al</i> , 2014, http://www.equator-network.org/reporting-guidelines/srqr/
COREQ	Qualitative research interviews and focus groups	Tong <i>et al</i> , 2007, http://www.equator-network.org/reporting-guidelines/coreq/
STARD	Diagnostic test accuracy studies	Bossuyt <i>et al</i> , 2015, http://www.equator-network.org/reporting-guidelines/stard/
TRIPOD	Studies developing, validating, or updating a prediction model, for either diagnosis or prognosis	Collins <i>et al</i> , 2015, http://www.equator-network.org/reporting-guidelines/tripod-statement/
REMARK	Tumour marker prognostic studies	McShane <i>et al</i> , 2005, http://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumour-marker-prognostic-studies-remark/
SQUIRE	Quality improvement in health care	Ogrinc <i>et al</i> , 2016, http://www.equator-network.org/reporting-guidelines/squire/
CHEERS	Economic evaluations of health interventions	Husereau <i>et al</i> , 2013, http://www.equator-network.org/reporting-guidelines/cheers/
ARRIVE	Bioscience research using laboratory animals	Kilkenny <i>et al</i> , 2012, http://www.equator-network.org/reporting-guidelines/improving-bioscience-research-reporting-the-arrive-guidelines-for-reporting-animal-research/
SPIRIT	Clinical trial protocols	Chan <i>et al</i> , 2013, http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/
PRISMA-P	Systematic reviews and meta-analysis protocols	Moher <i>et al</i> , 2015, http://www.equator-network.org/reporting-guidelines/prisma-protocols/

fully understood, replicated if desired, and used to inform future research. Some of these guidelines also have extensions, offering additional guidance. The guidelines can also be used by peer reviewers to check that research reports are complete, accurate reflections of the research undertaken (Levine and Kressel, 2016).

The best known guidelines are the CONSORT Statement (checklist shown in Supplementary File 1) for reporting randomised controlled trials (Schulz *et al*, 2010) and the STROBE Statement (checklist shown in Supplementary File 2) for reporting observational studies (von Elm *et al*, 2007). Although reporting guidelines should not be used to critically appraise reports of research studies, they prompt authors to report the information needed for a complete critical appraisal.

Generic guidelines exist for reporting most major types of clinical and pre-clinical research. They provide an excellent starting point when writing up any study, including oncology research. Other reporting guidelines that provide guidance on reporting specific aspects of study methods, procedures, or medical conditions, including oncology-specific guidelines, can be found in the database of reporting guidelines on the EQUATOR Network website. The Network systematically collects and classifies all reporting guidelines to help researchers easily find the guidelines relevant to their work.

There is increasing interest in the publication of protocols for research studies. Guidelines are available for preparing protocols for randomised trials (Chan *et al*, 2013) and systematic reviews (Moher *et al*, 2015).

EQUATOR ONCOLOGY

The UK EQUATOR Centre was awarded funding from Cancer Research UK to develop oncology-specific resources and activities to enhance the quality and transparency of published oncology research (<http://www.equator-network.org/library/equator-oncology/>).

We are reviewing the literature on the quality of reporting of clinical trials and observational studies in oncology. In the course of our work, we are collating published literature on oncology research methodology and reporting, which we regularly make available through the EQUATOR Oncology Current Awareness Bulletin.

The project focuses on research reporting, but in the next phase will be expanded to include guidance for efficient research planning and design. Ensuring robustness in the planning of any research project is the first condition for obtaining reliable research findings. For example, writing a detailed protocol documenting the study design and all methods forms the basis for the final written research manuscript. Guidelines already exist for preparing some types of research protocol, each linked with corresponding guidelines for reporting study findings. For example, the SPIRIT checklist (Chan *et al*, 2013) is used to guide the preparation of a protocol for a randomised controlled trial, with much overlap of concepts and structure with the CONSORT checklist (Schulz *et al*, 2010) for reporting trial findings.

Table 3. Oncology-specific reporting guidelines available on the EQUATOR website

Guideline provided for	Clinical area of study that guideline relates to	Section of study report that guideline relates to	No of citations of guideline	Guideline available via 'Open Access'	Guideline reference and link to more information about the guideline in the EQUATOR database [number]
(a) Guidance for reporting all parts of a study					
<i>1. Clinical trials</i>					
Myeloma clinical trials	Oncology, haematology	Whole report	186	Yes	Rajkumar <i>et al</i> , 2011 [1]
Phase 1 and phase 2 clinical trials in neuro-oncology	Oncology, neurology	Whole report	16	Yes	Chang <i>et al</i> , 2005 [2]
Surgically-based therapeutic clinical trials	Oncology, neurology, surgery	Whole report	8		Chang <i>et al</i> , 2007 [3]
Therapeutic trials in acute myeloid leukaemia (AML)	Oncology, haematology	Whole report	1149		Cheson <i>et al</i> , 2003 [4]
Clinical trials in cancer pain educational interventions	Oncology	Whole report	7	Yes	Stiles <i>et al</i> , 2010 [5]
<i>2. Observational studies</i>					
Tumour marker prognostic studies	Oncology, genetics	Whole report	313	Yes	McShane <i>et al</i> , 2005 [6]
The design and analysis of prognostic factor studies in non-small cell lung cancer (NSCLC)	Oncology, genetics, respiratory medicine	Whole report	151	Yes	Subramanian and Simon, 2010 [7]
(b) Guidance for reporting certain parts of a study					
<i>1. Clinical trials</i>					
Reporting of BCR-ABL molecular testing	Oncology, haematology	Procedure/method, results	4		Akard and Wang, 2011 [8]
Reporting clinical trial results on electrochemotherapy	Oncology	Procedure/method, study characteristics, intervention, results, data, outcomes, ethical issues, research recommendations	4	Yes	Campana <i>et al</i> , 2016 [9]
Standard definitions and endpoints for neoadjuvant clinical trials in breast cancer	Oncology	Terminology/definitions	23		Fumagalli <i>et al</i> , 2012 [10]
Clinical trials in systemic light-chain amyloidosis	Oncology, haematology	Procedure/method, study characteristics, outcomes	48		Comenzo <i>et al</i> , 2012 [11]
Clinical trials for patients in the state of a rising prostate-specific antigen	Oncology, urology	Study characteristics, outcomes	121	Yes	Scher <i>et al</i> , 2004 [12]
Flow cytometry minimal residual disease analysis and reporting in multiple myeloma	Oncology, haematology	Procedure/method, results	3	Yes	Arroz <i>et al</i> , 2016 [13]
Reporting system for correlation of cytogenetic and molecular genetic data with clinical data	Oncology, haematology	Procedure/method, intervention, outcomes	1094	Yes	Döhner <i>et al</i> , 2010 [14]
Reporting definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukaemia	Oncology	Terminology/definitions, statistical methods and analyses	30	Yes	Guilhot <i>et al</i> , 2012 [15]
Clinical platelet transfusion studies	Oncology, haematology	Procedure/method, intervention, outcomes, harms/adverse effects/safety data	2		Meyer <i>et al</i> , 2013 [16]
Reporting embolisation treatment of vascular head, neck and brain tumours	Oncology, neurology, radiology, surgery	Terminology/definitions	10	Yes	Duffis <i>et al</i> , 2012 [17]
Reporting MRI evaluation of response after neoadjuvant radiotherapy in soft tissue sarcoma	Oncology, radiology	Images	0	Yes	Messiou <i>et al</i> , 2016 [18]
To promote standardisation and diminish variations in the acquisition, interpretation, and reporting of whole-body MRI scans for use in advanced prostate cancer	Oncology, urology, radiology, nuclear medicine	Images	Reference not found	Yes	Padhani <i>et al</i> , 2017 [19]

Table 3. (Continued)

Guideline provided for	Clinical area of study that guideline relates to	Section of study report that guideline relates to	No of citations of guideline	Guideline available via 'Open Access'	Guideline reference and link to more information about the guideline in the EQUATOR database [number]
Reporting of post-neoadjuvant systemic therapy breast cancer specimens	Oncology, pathology	Procedure/method, study characteristics, terminology/definitions, intervention	4	Yes	Provenzano <i>et al</i> , 2015 [20]
Reporting of health-related quality of life in clinical cancer trials	Oncology	Outcomes	51		Lee and Chi, 2000 [21]
Use of historical data for determining "go/no go" decision for definitive phase III testing	Oncology	Procedure/method, data	32	Yes	Vickers <i>et al</i> , 2007 [22]
Common terminology criteria for paediatric reporting of adverse events in oncology trials	Oncology, paediatrics	Terminology/definitions, harms/adverse effects/safety data	Reference not found		Reeve <i>et al</i> , 2017 [23]
2. Observational studies					
Presenting prognostic studies with missing covariate data	Oncology	Data	87	Yes	Burton and Altman, 2004 [24]
Reporting case series of tumours of the colon and rectum	Oncology, gastroenterology, surgery	Procedure/method, study characteristics, intervention, results, data, outcomes	Journal indexed from 2008 onwards		Rubino and Pragnell, 1999 [25]
Reporting of individual MRI studies in men with prostate cancer on active surveillance and for reporting the outcomes of cohorts of men with prostate cancer having MRI on active surveillance	Oncology, urology, radiology	Images	Reference not found		Moore <i>et al</i> , 2017 [26]
3. Other study types					
Standards for balanced reporting on websites and in newspapers	Oncology, obstetrics & gynaecology		12		Bodemer <i>et al</i> , 2012 [27]
Reporting clinical studies of radioembolisation of hepatic malignancies	Oncology, gastroenterology, radiology	Procedure/method, study characteristics, terminology/definitions, intervention, images, outcomes, harms/adverse effects/safety data	78	Yes	Salem <i>et al</i> , 2011 [28]
Transcatheter therapies for hepatic malignancy	Oncology, gastroenterology, radiology, surgery	Procedure/method, study characteristics, terminology/definitions, outcomes, harms/adverse effects/safety data	51	Yes	Brown <i>et al</i> , 2009 [29]
Reporting clinical studies and research on the use of ablation methods for the treatment of benign bone tumours and metastases involving bone and soft tissues beyond the liver and lung	Oncology, radiology	Procedure/method, study characteristics, intervention, results, images, outcomes, harms/adverse effects/safety data	14	Yes	Callstrom <i>et al</i> , 2009 [30]
Percutaneous thermal ablation of primary renal cell carcinoma	Oncology, renal medicine, radiology, surgery	Procedure/method, study characteristics, terminology/definitions, intervention, images, outcomes, harms/adverse effects/safety data	19	Yes	Clark <i>et al</i> , 2009 [31]
Percutaneous vertebral augmentation	Oncology, rheumatology, radiology, surgery	Procedure/method, study characteristics, intervention, outcomes, harms/adverse effects/safety data	8	Yes	Radvany <i>et al</i> , 2009 [32]
Reporting the various aspects of image-guided ablation therapy	Oncology, radiology	Study characteristics, terminology/definitions, intervention, results, images, statistical methods and analyses, outcomes, harms/adverse effects/safety data	101	Yes	Ahmed <i>et al</i> , 2014 [33]

Table 3. (Continued)

Guideline provided for	Clinical area of study that guideline relates to	Section of study report that guideline relates to	No of citations of guideline	Guideline available via 'Open Access'	Guideline reference and link to more information about the guideline in the EQUATOR database [number]
Reporting image-guided irreversible electroporation ablation therapy	Oncology, radiology	Terminology/definitions, data, images	Reference not found	Yes	Wendler <i>et al</i> , 2016 [34]
Reporting and gathering data on dose-volume dependencies of treatment outcome	Oncology	Data	65	Yes	Jackson <i>et al</i> , 2010 [35]
Calibration methods in cancer simulation models	Oncology	Procedure/method, data	38		Stout <i>et al</i> , 2009 [36]
Reporting HIF-1 α -TG interactions	Oncology, genetics	Data	Reference not found		Slemc and Kunej, 2016 [37]

- [1] <http://www.equator-network.org/reporting-guidelines/consensus-recommendations-for-the-uniform-reporting-of-clinical-trials-report-of-the-international-myeloma-workshop-consensus-panel-1/>
- [2] <http://www.equator-network.org/reporting-guidelines/gnosis-guidelines-for-neuro-oncology-standards-for-investigational-studies-reporting-of-phase-1-and-phase-2-clinical-trials/>
- [3] <http://www.equator-network.org/reporting-guidelines/gnosis-guidelines-for-neuro-oncology-standards-for-investigational-studies-reporting-of-surgically-based-therapeutic-clinical-trials/>
- [4] <http://www.equator-network.org/reporting-guidelines/revise-recommendations-of-the-international-working-group-for-diagnosis-standardization-of-response-criteria-treatment-outcomes-and-reporting-standards-for-therapeutic-trials-in-acute-myeloid-leuk/>
- [5] <http://www.equator-network.org/reporting-guidelines/clinical-trials-focusing-on-cancer-pain-educational-interventions-core-components-to-include-during-planning-and-reporting/>
- [6] <http://www.equator-network.org/reporting-guidelines/reporting-recommendations-for-tumour-marker-prognostic-studies-remark/>
- [7] <http://www.equator-network.org/reporting-guidelines/gene-expression-based-prognostic-signatures-in-lung-cancer-ready-for-clinical-use/>
- [8] <http://www.equator-network.org/reporting-guidelines/translating-trial-based-molecular-monitoring-into-clinical-practice-importance-of-international-standards-and-practical-considerations-for-community-practitioners/>
- [9] <http://www.equator-network.org/reporting-guidelines/recommendations-for-improving-the-quality-of-reporting-clinical-electrochemotherapy-studies-based-on-qualitative-systematic-review/>
- [10] <http://www.equator-network.org/reporting-guidelines/a-common-language-in-neoadjuvant-breast-cancer-clinical-trials-proposals-for-standard-definitions-and-endpoints/>
- [11] <http://www.equator-network.org/reporting-guidelines/consensus-guidelines-for-the-conduct-and-reporting-of-clinical-trials-in-systemic-light-chain-amyloidosis/>
- [12] <http://www.equator-network.org/reporting-guidelines/eligibility-and-outcomes-reporting-guidelines-for-clinical-trials-for-patients-in-the-state-of-a-rising-prostate-specific-antigen-recommendations-from-the-prostate-specific-antigen-working-group/>
- [13] <http://www.equator-network.org/reporting-guidelines/consensus-guidelines-on-plasma-cell-myeloma-minimal-residual-disease-analysis-and-reporting/>
- [14] <http://www.equator-network.org/reporting-guidelines/diagnosis-and-management-of-acute-myeloid-leukemia-in-adults-recommendations-from-an-international-expert-panel-on-behalf-of-the-european-leukemianet/>
- [15] <http://www.equator-network.org/reporting-guidelines/definitions-methodological-and-statistical-issues-for-phase-3-clinical-trials-in-chronic-myeloid-leukemia-a-proposal-by-the-european-leukemianet/>
- [16] <http://www.equator-network.org/reporting-guidelines/a-reporting-guideline-for-clinical-platelet-transfusion-studies-from-the-best-collaborative/>
- [17] <http://www.equator-network.org/reporting-guidelines/head-neck-and-brain-tumor-embolization-guidelines/>
- [18] <http://www.equator-network.org/reporting-guidelines/evaluation-of-response-after-pre-operative-radiotherapy-in-soft-tissue-sarcomas-the-european-organisation-for-research-and-treatment-of-cancer-soft-tissue-and-bone-sarcoma-group-eortc-stbsg-and-ima/>
- [19] <http://www.equator-network.org/reporting-guidelines/metastasis-reporting-and-data-system-for-prostate-cancer-practical-guidelines-for-acquisition-interpretation-and-reporting-of-whole-body-magnetic-resonance-imaging-based-evaluations-of-multiorgan-i/>
- [20] <http://www.equator-network.org/reporting-guidelines/standardization-of-pathologic-evaluation-and-reporting-of-postneoadjuvant-specimens-in-clinical-trials-of-breast-cancer-recommendations-from-an-international-working-group/>
- [21] <http://www.equator-network.org/reporting-guidelines/the-standard-of-reporting-of-health-related-quality-of-life-in-clinical-cancer-trials/>
- [22] <http://www.equator-network.org/reporting-guidelines/setting-the-bar-in-phase-ii-trials-the-use-of-historical-data-for-determining-gono-go-decision-for-definitive-phase-iii-testing/>
- [23] <http://www.equator-network.org/reporting-guidelines/eliciting-the-childs-voice-in-adverse-event-reporting-in-oncology-trials-cognitive-interview-findings-from-the-pediatric-patient-reported-outcomes-version-of-the-common-terminology-criteria-for-ad/>
- [24] <http://www.equator-network.org/reporting-guidelines/missing-covariate-data-within-cancer-prognostic-studies-a-review-of-current-reporting-and-proposed-guidelines/>
- [25] <http://www.equator-network.org/reporting-guidelines/guidelines-for-reporting-case-series-of-tumours-of-the-colon-and-rectum/>
- [26] <http://www.equator-network.org/reporting-guidelines/reporting-magnetic-resonance-imaging-in-men-on-active-surveillance-for-prostate-cancer-the-precise-recommendations-a-report-of-a-european-school-of-oncology-task-force/>
- [27] <http://www.equator-network.org/reporting-guidelines/do-the-media-provide-transparent-health-information-a-cross-cultural-comparison-of-public-information-about-the-hpv-vaccine/>
- [28] <http://www.equator-network.org/reporting-guidelines/research-reporting-standards-for-radioembolization-of-hepatic-malignancies/>
- [29] <http://www.equator-network.org/reporting-guidelines/transcatheter-therapy-for-hepatic-malignancy-standardization-of-terminology-and-reporting-criteria/>
- [30] <http://www.equator-network.org/reporting-guidelines/research-reporting-standards-for-image-guided-ablation-of-bone-and-soft-tissue-tumors/>
- [31] <http://www.equator-network.org/reporting-guidelines/reporting-standards-for-percutaneous-thermal-ablation-of-renal-cell-carcinoma/>
- [32] <http://www.equator-network.org/reporting-guidelines/research-reporting-standards-for-percutaneous-vertebral-augmentation/>
- [33] <http://www.equator-network.org/reporting-guidelines/image-guided-tumor-ablation-standardization-of-terminology-and-reporting-criteria-a-10-year-update/>
- [34] <http://www.equator-network.org/reporting-guidelines/irreversible-electroporation-ire-standardization-of-terminology-and-reporting-criteria-for-analysis-and-comparison/>
- [35] <http://www.equator-network.org/reporting-guidelines/the-lessons-of-quantec-recommendations-for-reporting-and-gathering-data-on-dose-volume-dependencies-of-treatment-outcome/>
- [36] <http://www.equator-network.org/reporting-guidelines/calibration-methods-used-in-cancer-simulation-models-and-suggested-reporting-guidelines/>
- [37] <http://www.equator-network.org/reporting-guidelines/transcription-factor-hif1a-downstream-targets-associated-pathways-polymorphic-hypoxia-response-element-hre-sites-and-initiative-for-standardization-of-reporting-in-scientific-literature/>

A version of Table 3 with active links is provided online as Supplementary Table 1.

ONCOLOGY-SPECIFIC REPORTING GUIDELINES

The EQUATOR Network website already offers important resources to help authors write up oncology research studies. In October 2016 our regularly updated database of reporting guidelines included 37 oncology-specific guidelines. These guidelines complement the generic guidelines, offering

guidance on reporting aspects of various study types, such as observational studies, prognostic and diagnostic studies, and clinical trials.

Table 3 describes the 37 oncology-specific guidelines by the clinical area, study type, and section of the report that they refer to. Some cover oncology studies in general, while others focus on research in certain diagnostic groups, such as cancer of the lung, liver, breast, kidney, bone, and soft tissue. The fields of

haematology, neuro-oncology, urology, and gastroenterology are well-represented.

USE OF ONCOLOGY-SPECIFIC REPORTING GUIDELINES

The publication of a reporting guideline will not affect reporting completeness and quality unless researchers working in the field are aware of and use the guideline when they write their manuscripts. We investigated how many times each oncology-specific reporting guideline had been cited by other research papers. We searched the Web of Science Core Collection Science Citation Index Expanded (SCI-EXPANDED) from inception to the present (last search date 3 November 2016). The results of these citation searches are shown in Table 3.

Two guidelines have each been cited more than 1000 times. Both focus on haematology research, one covering the whole study report for trials in a particular disease (acute myeloid leukaemia, (Cheson *et al*, 2003)) and the other dealing with a particular kind of data (correlating genetic and clinical data (Döhner *et al*, 2010)). Five have been cited between 100 and 350 times, and 23 have been cited less than 100 times. One guideline had no citations but was only published in 2016, and six guidelines were not found in the Citation Index.

It is likely that many authors who use a reporting guideline do not actually cite it, and that not all research papers that cite a guideline do so because it was used to help write the paper. Nevertheless, the citation numbers give a rough indication of the use of each guideline in the literature. Many factors will influence the differences between the citation rates of specific guidelines, for example the size of the subspecialty within oncology and when the guideline was published.

Journals have an important role to play in improving reporting of research studies by highlighting the use of reporting guidelines in their instructions to authors. Reporting guidelines can also be very helpful for peer-reviewers. The EQUATOR Network has produced a new toolkit to help journals to publish clear and therefore usable research reports (<http://www.equator-network.org/toolkits/using-guidelines-in-journals/>).

FUTURE WORK OF EQUATOR ONCOLOGY

Health research reporting problems have been well-documented in recent years, and oncology research is no exception (Papathanasiou and Zintzaras, 2010; Peron *et al*, 2012, 2013; Jankova *et al*, 2015; Maillet *et al*, 2016; Sivendran and Galsky, 2016). Despite these continuing reporting issues, two specific guidelines for haematology research have been very well cited. The question remains as to why authors do not use existing reporting guidelines. Is it because authors need additional specific guidelines for certain oncology study types, because authors need help to better use existing guidelines (both generic and specific), because they do not think reporting guidelines are worth the effort, or because they are simply unaware that reporting guidelines exist?

EQUATOR Oncology aims to highlight the real-life consequences of poor reporting, to provide resources and to support oncology researchers by helping them to find and use the appropriate reporting guidelines for their research.

Peer-reviewers also play an important role in the process of improving research reporting, and reporting guidelines can be a helpful tool for those reviewing manuscripts prior to publication. However, checking adherence to a reporting guideline can be time-consuming. It may be helpful for guideline developers to produce short lists of items for peer reviewers to focus their attention on.

We will establish an EQUATOR Oncology 'Advisory Group' of experts and opinion leaders in oncology research including clinicians, oncologists, methodologists, editors, Cancer Research UK and EQUATOR representatives – who will oversee and inform the development of the project. Based on our findings from literature reviews and advice from our expert advisory group, we will identify issues and develop oncology-specific online resources to help minimise reporting problems and increase the impact of published oncology research.

We will also carry out surveys of oncology researchers, oncology journal editors and peer reviewers to identify their concerns about reporting in journal articles.

Our web resources can help oncology researchers improve their research reporting in manuscripts and will ultimately help to improve the robustness and reliability of the research itself. Only with the expert help of authors, researchers, methodologists, opinion leaders, and journal editors working in cancer research can our online resources fully address the reporting issues that oncology researchers need assistance with. We encourage those involved in cancer research to contact us with suggestions for the development of these resources.

Cancer patients take part in research studies to try to improve their health conditions and for altruistic reasons (Moorcraft *et al*, 2016). Their contributions to scientific understanding should not be wasted because the research is poorly conducted, inadequately reported, or even not reported at all. EQUATOR Oncology will support oncology researchers to conduct robust research and to produce research papers that are usable, reproducible, and transparent, recognising the important contributions of all patient participants in research.

ACKNOWLEDGEMENTS

This work was supported by Cancer Research UK (C5529/A16895). The work was carried out in the Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology & Musculoskeletal Sciences, University of Oxford, UK.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

- Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, Chen MH, Choi BI, de Baere T, Dodd 3rd GD, Dupuy DE, Gervais DA, Gianfelice D, Gillams AR, Lee Jr FT, Leen E, Lencioni R, Littrup PJ, Livraghi T, Lu DS, McGahan JP, Meloni MF, Nikolic B, Pereira PL, Liang P, Rhim H, Rose SC, Salem R, Sofocleous CT, Solomon SB, Soulen MC, Tanaka M, Vogl TJ, Wood BJ, Goldberg SN (2014) Image-guided tumor ablation: standardization of terminology and reporting criteria – a 10-year update. *Radiology* **273**(1): 241–260.
- Akard LP, Wang YL (2011) Translating trial-based molecular monitoring into clinical practice: importance of international standards and practical considerations for community practitioners. *Clin Lymphoma Myeloma Leuk* **11**(5): 385–395.
- Altwaigri AK, Alfakeeh AH, Hopman WM, Parulekar WR (2015) Quality of reporting of chemotherapy compliance in randomized controlled trials of breast cancer treatment. *Jpn J Clin Oncol* **45**(6): 520–526.
- Altwaigri AK, Booth CM, Hopman WM, Baetz TD (2012) Discordance between conclusions stated in the abstract and conclusions in the article: analysis of published randomized controlled trials of systemic therapy in lung cancer. *J Clin Oncol* **30**(28): 3552–3557.
- Arroz M, Came N, Lin P, Chen W, Yuan C, Lagoo A, Monreal M, de Tute R, Vergilio JA, Rawstron AC, Paiva B (2016) Consensus guidelines on plasma

- cell myeloma minimal residual disease analysis and reporting. *Cytometry B Clin Cytom* **90**(1): 31–39.
- Bodemer N, Muller SM, Okan Y, Garcia-Retamero R, Neumeier-Gromen A (2012) Do the media provide transparent health information? A cross-cultural comparison of public information about the HPV vaccine. *Vaccine* **30**(25): 3747–3756.
- Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, Lijmer JG, Moher D, Rennie D, de Vet HC, Kressel HY, Rifai N, Golub RM, Altman DG, Hooft L, Korevaar DA, Cohen JF (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *Radiology* **277**(3): 826–832.
- Brazma A, Hingamp P, Quackenbush J, Sherlock G, Spellman P, Stoeckert C, Aach J, Ansorge W, Ball CA, Causton HC, Gaasterland T, Glenisson P, Holstege FC, Kim IF, Markowitz V, Matese JC, Parkinson H, Robinson A, Sarkans U, Schulze-Kremer S, Stewart J, Taylor R, Vilo J, Vingron M (2001) Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. *Nat Genet* **29**(4): 365–371.
- Brown DB, Gould JE, Gervais DA, Goldberg SN, Murthy R, Millward SF, Rilling WS, Geschwind JF, Salem R, Vedantham S, Cardella JF, Soulen MC, Society of Interventional Radiology Technology Assessment Cthe International Working Group on Image-Guided Tumor A (2009) Transcatheter therapy for hepatic malignancy: standardization of terminology and reporting criteria. *J Vasc Interv Radiol* **20**(7 Suppl): S425–S434.
- Burton A, Altman DG (2004) Missing covariate data within cancer prognostic studies: a review of current reporting and proposed guidelines. *Br J Cancer* **91**(1): 4–8.
- Bylicki O, Gan HK, Joly F, Maillet D, You B, Peron J (2015) Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. *Ann Oncol* **26**(1): 231–237.
- Callstrom MR, York JD, Gaba RC, Gemmete JJ, Gervais DA, Millward SF, Brown DB, Dupuy D, Goldberg SN, Kundu S, Rose SC, Thomas JJ, Cardella JF, Technology Assessment Committee of Society of Interventional R (2009) Research reporting standards for image-guided ablation of bone and soft tissue tumors. *J Vasc Interv Radiol* **20**(12): 1527–1540.
- Campana LG, Clover AJ, Valpione S, Quaglini P, Gehl J, Kunte C, Snoj M, Cemazar M, Rossi CR, Miklavcic D, Sersa G (2016) Recommendations for improving the quality of reporting clinical electrochemotherapy studies based on qualitative systematic review. *Radiol Oncol* **50**(1): 1–13.
- Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleza-Jeric K, Hrobjartsson A, Mann H, Dickersin K, Berlin JA, Dore CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D (2013) SPIRIT 2013 statement: defining standard protocol items for clinical trials. *Ann Intern Med* **158**(3): 200–207.
- Chang S, Vogelbaum M, Lang FF, Haines S, Kunwar S, Chiocca EA, Olivi A, Quinones-Hinojosa A, Parsa A, Warnick R (2007) GNOSES: guidelines for neuro-oncology: standards for investigational studies—reporting of surgically based therapeutic clinical trials. *J Neurooncol* **82**(2): 211–220.
- Chang SM, Reynolds SL, Butowski N, Lamborn KR, Buckner JC, Kaplan RS, Bigner DD (2005) GNOSES: guidelines for neuro-oncology: standards for investigational studies—reporting of phase 1 and phase 2 clinical trials. *Neuro Oncol* **7**(4): 425–434.
- Cheson BD, Bennett JM, Kopecck KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. *J Clin Oncol* **21**(24): 4642–4649.
- Clark TW, Millward SF, Gervais DA, Goldberg SN, Grassi CJ, Kinney TB, Phillips DA, Sacks D, Cardella JF, Technology Assessment Committee of the Society of Interventional R (2009) Reporting standards for percutaneous thermal ablation of renal cell carcinoma. *J Vasc Interv Radiol* **20**(7 Suppl): S409–S416.
- Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): the TRIPOD statement. *Ann Intern Med* **162**(1): 55–63.
- Comenzo RL, Reece D, Palladini G, Seldin D, Sanchowawala V, Landau H, Falk R, Wells K, Solomon A, Wechalekar A, Zonder J, Dispenzieri A, Gertz M, Streicher H, Skinner M, Kyle RA, Merlini G (2012) Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. *Leukemia* **26**(11): 2317–2325.
- Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. *Blood* **115**(3): 453–474.
- Duff JM, Leather H, Walden EO, LaPlant KD, George TJ Jr (2010) Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. *J Natl Cancer Inst* **102**(10): 702–705.
- Duffis EJ, Gandhi CD, Prestigiacomo CJ, Abruzzo T, Albuquerque F, Bulsara KR, Derdeyn CP, Fraser JF, Hirsch JA, Hussain MS, Do HM, Jayaraman MV, Meyers PM, Narayanan S (2012) Head, neck, and brain tumor embolization guidelines. *J Neurointerv Surg* **4**(4): 251–255.
- Fumagalli D, Bedard PL, Nahleh Z, Michiels S, Sotiriou C, Loi S, Sparano JA, Ellis M, Hylton N, Zujewski JA, Hudis C, Esserman L, Piccart M (2012) A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. *Lancet Oncol* **13**(6): e240–e248.
- Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D (2014) The CARE guidelines: consensus-based clinical case report guideline development. *J Clin Epidemiol* **67**(1): 46–51.
- Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, Michie S, Moher D, Wager E (2014) Reducing waste from incomplete or unusable reports of biomedical research. *Lancet* **383**(9913): 267–276.
- Goodman SN, Fanelli D, Ioannidis JP (2016) What does research reproducibility mean? *Sci Transl Med* **8**(341): 341ps12.
- Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritsky A, Hehlmann R (2012) Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. *Blood* **119**(25): 5963–5971.
- Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J, Loder E (2013) Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMC Med* **11**: 80.
- Jackson A, Marks LB, Bentzen SM, Eisbruch A, Yorke ED, Ten Haken RK, Constine LS, Deasy JO (2010) The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volume dependencies of treatment outcome. *Int J Radiat Oncol Biol Phys* **76**(3 Suppl): S155–S160.
- Jankova L, Dent OF, Molloy MP, Chan C, Chapuis PH, Howell VM, Clarke SJ (2015) Reporting in studies of protein biomarkers of prognosis in colorectal cancer in relation to the REMARK guidelines. *Proteomics Clin Appl* **9**(11–12): 1078–1086.
- Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG (2012) Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. *Osteoarthritis Cartilage* **20**(4): 256–260.
- Kyzas PA, Denaxa-Kyza D, Ioannidis JP (2007) Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. *J Natl Cancer Inst* **99**(3): 236–243.
- Lee CW, Chi KN (2000) The standard of reporting of health-related quality of life in clinical cancer trials. *J Clin Epidemiol* **53**(5): 451–458.
- Levine D, Kressel HY (2016) 2016: reviewing for radiology – reporting guidelines and why we use them. *Radiology* **280**(3): 659–662.
- Maillet D, Blay JY, You B, Rachdi A, Gan HK, Peron J (2016) The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. *Ann Oncol* **27**(1): 192–198.
- McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer* **93**(4): 387–391.
- Meghelli L, Narducci F, Mariette C, Piessen G, Vanseymortier M, Leblanc E, Collinet P, Duhamel A, Penel N (2016) Reporting adverse events in cancer surgery randomized trials: a systematic review of published trials in

- oesophago-gastric and gynecological cancer patients. *Crit Rev Oncol Hematol* **104**: 108–114.
- Messiou C, Bonvalot S, Gronchi A, Vanel D, Meyer M, Robinson P, Morosi C, Bloem JL, Terrier PH, Lazar A, Le Pechoux C, Wardelman E, Winfield JM, Boulet B, Bovee J, Haas RL (2016) Evaluation of response after pre-operative radiotherapy in soft tissue sarcomas; the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) and Imaging Group recommendations for radiological examination and reporting with an emphasis on magnetic resonance imaging. *Eur J Cancer* **56**: 37–44.
- Meyer E, Delaney M, Lin Y, Morris A, Pavenski K, Timmouth A, Murphy M, Slichter SJ, Heddle N, Dumont LJ (2013) A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. *Transfusion* **53**(6): 1328–1334.
- Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. *Cancer* **47**(1): 207–214.
- Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* **62**(10): 1006–1012.
- Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* **4**: 1.
- Moorcraft SY, Marriott C, Peckitt C, Cunningham D, Chau I, Starling N, Watkins D, Rao S (2016) Patients' willingness to participate in clinical trials and their views on aspects of cancer research: results of a prospective patient survey. *Trials* **17**: 17.
- Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijera K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I (2017) Reporting magnetic resonance imaging in men on active surveillance for prostate cancer: the PRECISE recommendations – a report of a European School of Oncology Task Force. *Eur Urol* **71**(4): 648–655.
- Nahum AM (1979) Biting the bullet: minimum standards for reporting cancer treatment statistics. *Head Neck Surg* **1**(3): 201.
- O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA (2014) Standards for reporting qualitative research: a synthesis of recommendations. *Acad Med* **89**(9): 1245–1251.
- Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D (2016) SQUIRE 2.0 (Standards for QQuality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. *BMJ Qual Saf* **25**(12): 986–992.
- Padhani AR, Lecouvet FE, Tunariu N, Koh DM, De Keyser F, Collins DJ, Sala E, Schlemmer HP, Petralia G, Vargas HA, Fanti S, Tombal HB, de Bono J (2017) METastasis reporting and data system for prostate cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. *Eur Urol* **71**(1): 81–92.
- Papathanasiou AA, Zintzaras E (2010) Assessing the quality of reporting of observational studies in cancer. *Ann Epidemiol* **20**(1): 67–73.
- Peron J, Maillet D, Gan HK, Chen EX, You B (2013) Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic review. *J Clin Oncol* **31**(31): 3957–3963.
- Peron J, Pond GR, Gan HK, Chen EX, Almufti R, Maillet D, You B (2012) Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. *J Natl Cancer Inst* **104**(13): 982–989.
- Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF (2015) Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol* **28**(9): 1185–1201.
- Radvany MG, Murphy KJ, Millward SF, Barr JD, Clark TW, Halin NJ, Kinney TB, Kundu S, Sacks D, Wallace MJ, Cardella JF, Technology Assessment Committee of the Society of Interventional R (2009) Research reporting standards for percutaneous vertebral augmentation. *J Vasc Interv Radiol* **20**(10): 1279–1286.
- Raghav KP, Mahajan S, Yao JC, Hobbs BP, Berry DA, Pentz RD, Tam A, Hong WK, Ellis LM, Abbruzzese J, Overman MJ (2015) From protocols to publications: a study in selective reporting of outcomes in randomized trials in oncology. *J Clin Oncol* **33**(31): 3583–3590.
- Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orłowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J (2011) Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. *Blood* **117**(18): 4691–4695.
- Reeve BB, McFatrigh M, Pinheiro LC, Weaver MS, Sung L, Withycombe JS, Baker JN, Mack JW, Waldron MK, Gibson D, Tomlinson D, Freyer DR, Mowbray C, Jacobs S, Palma D, Martens CE, Gold SH, Jackson KD, Hinds PS (2017) Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. *Pediatr Blood Cancer* **64**(3): e26261.
- Rubino M, Pragnell MVC (1999) Guidelines for reporting case series of tumours of the colon and rectum. *Tech Coloproctol* **3**(2): 93–97.
- Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, Soulen MC, Geschwind JF, Kulik L, Kim YH, Spreafico C, Maccauro M, Bester L, Brown DB, Ryu RK, Sze DY, Rilling WS, Sato KT, Sangro B, Bilbao JJ, Jakobs TF, Ezziddin S, Kulkarni S, Kulkarni A, Liu DM, Valenti D, Hilgard P, Antoch G, Muller SP, Alsuhaibani H, Mulcahy MF, Burrell M, Real MI, Spies S, Esmail AA, Raoul JL, Garin E, Johnson MS, Benson 3rd AB, Sharma RA, Wasan H, Lambert B, Memon K, Kennedy AS, Riaz A, Technology Assessment C, Interventional Oncology Task Force of the Society of Interventional R (2011) Research reporting standards for radioembolization of hepatic malignancies. *J Vasc Interv Radiol* **22**(3): 265–278.
- Scher HI, Eisenberger M, D'Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR (2004) Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. *J Clin Oncol* **22**(3): 537–556.
- Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. *Ann Intern Med* **152**(11): 726–732.
- Sekula P, Pressler JB, Sauerbrei W, Goebell PJ, Schmitz-Dräger BJ (2016) Assessment of the extent of unpublished studies in prognostic factor research: a systematic review of p53 immunohistochemistry in bladder cancer as an example. *BMJ open* **6**(8): e009972.
- Sivendran S, Galsky MD (2016) Adverse event reporting in oncology clinical trials – lost in translation? *Expert Opin Drug Saf* **15**(7): 893–896.
- Slemc L, Kunej T (2016) Transcription factor HIF1A: downstream targets, associated pathways, polymorphic hypoxia response element (HRE) sites, and initiative for standardization of reporting in scientific literature. *Tumour Biol* **37**(11): 14851–14861.
- Stiles CR, Biondo PD, Cummings G, Hagen NA (2010) Clinical trials focusing on cancer pain educational interventions: core components to include during planning and reporting. *J Pain Symptom Manage* **40**(2): 301–308.
- Stout NK, Knudsen AB, Kong CY, McMahon PM, Gazelle GS (2009) Calibration methods used in cancer simulation models and suggested reporting guidelines. *Pharmacoeconomics* **27**(7): 533–545.
- Subramanian J, Simon R (2010) Gene expression-based prognostic signatures in lung cancer: ready for clinical use? *J Natl Cancer Inst* **102**(7): 464–474.
- Tam VC, Tannock IF, Massey C, Rauw J, Krzyzanowska MK (2011) Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practice. *J Clin Oncol* **29**(23): 3133–3139.
- Tong A, Sainsbury P, Craig J (2007) Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care* **19**(6): 349–357.

- Unknown (1979) WHO Handbook for Reporting Results of Cancer treatment. WHO Handbook for Reporting Results of Cancer treatment Offset publication No.48.
- Vera-Badillo FE, Napoleone M, Krzyzanowska MK, Alibhai SM, Chan AW, Ocana A, Seruga B, Templeton AJ, Amir E, Tannock IF (2016) Bias in reporting of randomised clinical trials in oncology. *Eur J Cancer* **61**: 29–35.
- Vickers AJ, Ballen V, Scher HI (2007) Setting the bar in phase II trials: the use of historical data for determining 'go/no go' decision for definitive phase III testing. *Clin Cancer Res* **13**(3): 972–976.
- von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP (2007) Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ* **335**(7624): 806–808.
- Wendler JJ, Fischbach K, Rieke J, Jurgens J, Fischbach F, Kollermann J, Porsch M, Baumunk D, Schostak M, Liehr UB, Pech M (2016) Irreversible Electroporation (IRE): standardization of terminology and reporting criteria for analysis and comparison. *Pol J Radiol* **81**: 54–64.



This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) named above 2018

Supplementary Information accompanies this paper on British Journal of Cancer website (<http://www.nature.com/bjc>)